

Avi Ashkenazi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5693433/avi-ashkenazi-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

160 papers	33,634 citations	83 h-index	183 g-index
184 ext. papers	35,841 ext. citations	14.8 avg, IF	7.26 L-index

#	Paper	IF	Citations
160	Pumilio protects Xbp1 mRNA from regulated Ire1-dependent decay.. <i>Nature Communications</i> , 2022 , 13, 1587	17.4	1
159	Steroid-induced fibroblast growth factors drive an epithelial-mesenchymal inflammatory axis in severe asthma.. <i>Science Translational Medicine</i> , 2022 , 14, eabl8146	17.5	1
158	The stress-sensing domain of activated IRE1 α forms helical filaments in narrow ER membrane tubes. <i>Science</i> , 2021 , 374, 52-57	33.3	5
157	Decoding non-canonical mRNA decay by the endoplasmic-reticulum stress sensor IRE1 α <i>Nature Communications</i> , 2021 , 12, 7310	17.4	4
156	Activation of the IRE1 RNase through remodeling of the kinase front pocket by ATP-competitive ligands. <i>Nature Communications</i> , 2020 , 11, 6387	17.4	8
155	Misfolded proteins bind and activate death receptor 5 to trigger apoptosis during unresolved endoplasmic reticulum stress. <i>ELife</i> , 2020 , 9,	8.9	37
154	Identification of BRAf-Sparing Amino-Thienopyrimidines with Potent IRE1 α Inhibitory Activity. <i>ACS Medicinal Chemistry Letters</i> , 2020 , 11, 2389-2396	4.3	2
153	IRE1 α Disruption in Triple-Negative Breast Cancer Cooperates with Antiangiogenic Therapy by Reversing ER Stress Adaptation and Remodeling the Tumor Microenvironment. <i>Cancer Research</i> , 2020 , 80, 2368-2379	10.1	11
152	Tetavalent biepitopic targeting enables intrinsic antibody agonism of tumor necrosis factor receptor superfamily members. <i>MAbs</i> , 2019 , 11, 996-1011	6.6	12
151	Caspase-mediated cleavage of IRE1 controls apoptotic cell commitment during endoplasmic reticulum stress. <i>ELife</i> , 2019 , 8,	8.9	20
150	Disruption of IRE1 α through its kinase domain attenuates multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 16420-16429	11.5	40
149	Confirming a critical role for death receptor 5 and caspase-8 in apoptosis induction by endoplasmic reticulum stress. <i>Cell Death and Differentiation</i> , 2018 , 25, 1530-1531	12.7	21
148	Coordination between Two Branches of the Unfolded Protein Response Determines Apoptotic Cell Fate. <i>Molecular Cell</i> , 2018 , 71, 629-636.e5	17.6	75
147	From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. <i>Nature Reviews Drug Discovery</i> , 2017 , 16, 273-284	64.1	467
146	Uncovering a Dual Regulatory Role for Caspases During Endoplasmic Reticulum Stress-induced Cell Death. <i>Molecular and Cellular Proteomics</i> , 2016 , 15, 2293-307	7.6	6
145	Antitherapeutic antibody-mediated hepatotoxicity of recombinant human Apo2L/TRAIL in the cynomolgus monkey. <i>Cell Death and Disease</i> , 2016 , 7, e2338	9.8	13
144	MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation. <i>EBioMedicine</i> , 2015 , 2, 406-20	8.8	7

143	Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study. <i>Lancet Haematology</i> , 2015 , 2, e166-74	14.6	29
142	TRAF2 is a biologically important necroptosis suppressor. <i>Cell Death and Differentiation</i> , 2015 , 22, 1846-57	5.7	51
141	Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2270-8	6.1	5
140	Membrane display and functional analysis of juxtacrine ligand-receptor signaling. <i>BioTechniques</i> , 2015 , 59, 231-8, 240	2.5	1
139	Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 5679-84	11.5	55
138	Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions. <i>Journal of Clinical Investigation</i> , 2015 , 125, 487-9	15.9	154
137	Is SIRT2 required for necroptosis?. <i>Nature</i> , 2014 , 506, E4-6	50.4	19
136	Regulated cell death: signaling and mechanisms. <i>Annual Review of Cell and Developmental Biology</i> , 2014 , 30, 337-56	12.6	167
135	Designer proteins to trigger cell death. <i>Cell</i> , 2014 , 157, 1506-8	56.2	3
134	Apoptosis initiation through the cell-extrinsic pathway. <i>Methods in Enzymology</i> , 2014 , 544, 99-128	1.7	58
133	Opposing unfolded-protein-response signals converge on death receptor 5 to control apoptosis. <i>Science</i> , 2014 , 345, 98-101	33.3	378
132	AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs. <i>Cancer Research</i> , 2014 , 74, 5878-80	10.1	101
131	Inflammasome-dependent and -independent IL-18 production mediates immunity to the ISCOMATRIX adjuvant. <i>Journal of Immunology</i> , 2014 , 192, 3259-68	5.3	53
130	E-cadherin couples death receptors to the cytoskeleton to regulate apoptosis. <i>Molecular Cell</i> , 2014 , 54, 987-98	17.6	73
129	MMP-1 and Pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 6324-35	12.9	17
128	A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2013 , 12, 248-54	3.8	42
127	ImmunoPET imaging of phosphatidylserine in pro-apoptotic therapy treated tumor models. <i>Nuclear Medicine and Biology</i> , 2013 , 40, 15-22	2.1	18
126	FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer. <i>Cancer Biology and Therapy</i> , 2013 , 14, 711-9	4.6	10

125	Host genetic background impacts modulation of the TLR4 pathway by RON in tissue-associated macrophages. <i>Immunology and Cell Biology</i> , 2013 , 91, 451-60	5	16
124	Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies. <i>Journal of Experimental Medicine</i> , 2013 , 210, 1647-51	16.6	30
123	Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 1245-54	6.1	65
122	Pharmacological brake-release of mRNA translation enhances cognitive memory. <i>ELife</i> , 2013 , 2, e00498	8.9	377
121	Complementary proteomic tools for the dissection of apoptotic proteolysis events. <i>Journal of Proteome Research</i> , 2012 , 11, 2947-54	5.6	23
120	TRAF2 Sets a threshold for extrinsic apoptosis by tagging caspase-8 with a ubiquitin shutoff timer. <i>Molecular Cell</i> , 2012 , 48, 888-99	17.6	110
119	ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway. <i>Immunology and Cell Biology</i> , 2012 , 90, 540-52	5	70
118	Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. <i>PLoS ONE</i> , 2012 , 7, e36733	3.7	143
117	Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth. <i>Cancer Cell</i> , 2012 , 22, 80-90	24.3	49
116	Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 2541-6	6.1	47
115	FGFR3 stimulates stearyl CoA desaturase 1 activity to promote bladder tumor growth. <i>Cancer Research</i> , 2012 , 72, 5843-55	10.1	58
114	NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-α feedforward signaling. <i>Cell</i> , 2011 , 145, 92-103	56.2	215
113	Snapshot: caspases. <i>Cell</i> , 2011 , 147, 476-476.e1	56.2	39
112	An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. <i>Cancer Cell</i> , 2011 , 19, 101-13	24.3	206
111	Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4442-51	2.2	191
110	Distinct involvement of the Gab1 and Grb2 adaptor proteins in signal transduction by the related receptor tyrosine kinases RON and MET. <i>Journal of Biological Chemistry</i> , 2011 , 286, 32762-74	5.4	19
109	TWEAK induces apoptosis through a death-signaling complex comprising receptor-interacting protein 1 (RIP1), Fas-associated death domain (FADD), and caspase-8. <i>Journal of Biological Chemistry</i> , 2011 , 286, 21546-54	5.4	69
108	New insights into apoptosis signaling by Apo2L/TRAIL. <i>Oncogene</i> , 2010 , 29, 4752-65	9.2	280

107	Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab. <i>Clinical Cancer Research</i> , 2010 , 16, 1587-96	12.9	34
106	Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2839-46	2.2	346
105	A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. <i>Clinical Cancer Research</i> , 2010 , 16, 1256-63	12.9	136
104	UNCovering the molecular machinery of dependence receptor signaling. <i>Molecular Cell</i> , 2010 , 40, 851-3	17.6	3
103	The zebrafish as a model organism for the study of apoptosis. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2010 , 15, 331-49	5.4	97
102	Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. <i>Current Opinion in Cell Biology</i> , 2010 , 22, 837-44	9	115
101	X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists. <i>Journal of Biological Chemistry</i> , 2009 , 284, 34553-60	5.4	50
100	Death receptor signal transducers: nodes of coordination in immune signaling networks. <i>Nature Immunology</i> , 2009 , 10, 348-55	19.1	416
99	Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. <i>Cell</i> , 2009 , 137, 721-35	56.2	484
98	Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. <i>Journal of Clinical Investigation</i> , 2009 , 119, 1216-29	15.9	185
97	Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. <i>Oncogene</i> , 2008 , 27, 85-97	9.2	202
96	Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. <i>Nature Reviews Drug Discovery</i> , 2008 , 7, 1001-12	64.1	331
95	Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. <i>Cell Death and Differentiation</i> , 2008 , 15, 751-61	12.7	125
94	Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). <i>Journal of Clinical Oncology</i> , 2008 , 26, 3621-30	2.2	355
93	Targeting the extrinsic apoptosis pathway in cancer. <i>Cytokine and Growth Factor Reviews</i> , 2008 , 19, 325-34	11.9	319
92	Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 2599-608	6.1	36
91	Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. <i>Clinical Cancer Research</i> , 2008 , 14, 7733-40	12.9	49
90	To kill a tumor cell: the potential of proapoptotic receptor agonists. <i>Journal of Clinical Investigation</i> , 2008 , 118, 1979-90	15.9	247

89	Secreted sulfatases Sulf1 and Sulf2 have overlapping yet essential roles in mouse neonatal survival. <i>PLoS ONE</i> , 2007 , 2, e575	3.7	98
88	Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. <i>Nature Medicine</i> , 2007 , 13, 1070-7	50.5	477
87	Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma cells and suppresses the growth of xenografts in nude mice. <i>Gene Therapy</i> , 2007 , 14, 147-61	4	26
86	Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. <i>Blood</i> , 2007 , 110, 4037-46	2.2	91
85	Death-receptor activation halts clathrin-dependent endocytosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 10283-10288	11.5	95
84	Activation of the proapoptotic death receptor DR5 by oligomeric peptide and antibody agonists. <i>Journal of Molecular Biology</i> , 2006 , 361, 522-36	6.5	43
83	Delineation of the cell-extrinsic apoptosis pathway in the zebrafish. <i>Cell Death and Differentiation</i> , 2006 , 13, 1619-30	12.7	87
82	Functional characterization of the Bcl-2 gene family in the zebrafish. <i>Cell Death and Differentiation</i> , 2006 , 13, 1631-40	12.7	107
81	TWEAK attenuates the transition from innate to adaptive immunity. <i>Cell</i> , 2005 , 123, 931-44	56.2	180
80	TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice. <i>Immunology and Cell Biology</i> , 2005 , 83, 511-9	5	53
79	Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. <i>Journal of Biological Chemistry</i> , 2005 , 280, 2205-12	5.4	215
78	Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. <i>Journal of Biological Chemistry</i> , 2005 , 280, 19401-9	5.4	120
77	Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. <i>Journal of Biological Chemistry</i> , 2005 , 280, 40599-608	5.4	203
76	APRIL-deficient mice have normal immune system development. <i>Molecular and Cellular Biology</i> , 2004 , 24, 997-1006	4.8	158
75	Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. <i>Cancer Research</i> , 2004 , 64, 4900-5	10.1	106
74	Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. <i>Cancer Research</i> , 2004 , 64, 9105-14	10.1	65
73	Targeting death receptors in cancer with Apo2L/TRAIL. <i>Current Opinion in Pharmacology</i> , 2004 , 4, 333-9	5.1	312
72	Tumor necrosis factor: an apoptosis JuNKie?. <i>Cell</i> , 2004 , 116, 491-7	56.2	434

71	Apo2L/TRAIL and its death and decoy receptors. <i>Cell Death and Differentiation</i> , 2003 , 10, 66-75	12.7	726
70	Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. <i>Cytokine and Growth Factor Reviews</i> , 2003 , 14, 337-48	17.9	466
69	Design, construction, and in vitro analyses of multivalent antibodies. <i>Journal of Immunology</i> , 2003 , 170, 4854-61	5.3	49
68	Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. <i>Nature Medicine</i> , 2002 , 8, 274-81	50.5	458
67	Targeting death and decoy receptors of the tumour-necrosis factor superfamily. <i>Nature Reviews Cancer</i> , 2002 , 2, 420-30	31.3	1092
66	Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. <i>American Journal of Pathology</i> , 2002 , 161, 643-54	5.8	63
65	Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. <i>Nature Medicine</i> , 2001 , 7, 383-5	50.5	641
64	TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. <i>Nature Immunology</i> , 2001 , 2, 632-7	19.1	178
63	Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. <i>Journal of Immunology</i> , 2001 , 166, 4891-8	5.3	192
62	Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. <i>Journal of Biological Chemistry</i> , 2001 , 276, 46639-46	5.4	373
61	Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages. <i>Scandinavian Journal of Immunology</i> , 2000 , 51, 244-50	3.4	84
60	Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. <i>Nature Immunology</i> , 2000 , 1, 37-41	19.1	195
59	Response to B-secreted IgM versus BLyS in germinal center formation. <i>Nature Immunology</i> , 2000 , 1, 179	19.1	
58	Combining enhanced metabolic labeling with immunoblotting to detect interactions of endogenous cellular proteins. <i>BioTechniques</i> , 2000 , 29, 506-10, 512	2.5	1
57	Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. <i>Immunity</i> , 2000 , 12, 611-20	32.3	830
56	Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. <i>Current Biology</i> , 2000 , 10, 785-8	6.3	347
55	A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. <i>Biochemistry</i> , 2000 , 39, 633-40	3.2	233
54	Apoptosis control by death and decoy receptors. <i>Current Opinion in Cell Biology</i> , 1999 , 11, 255-60	9	1113

53	Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GTR. <i>Current Biology</i> , 1999 , 9, 215-8	6.3	168
52	Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. <i>Molecular Cell</i> , 1999 , 4, 563-71	17.6	360
51	Safety and antitumor activity of recombinant soluble Apo2 ligand. <i>Journal of Clinical Investigation</i> , 1999 , 104, 155-62	15.9	1732
50	Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. <i>Biochemical and Biophysical Research Communications</i> , 1999 , 265, 479-83	3.4	188
49	Regulation of APO-2 ligand/trail expression in NK cells-involvement in NK cell-mediated cytotoxicity. <i>Cytokine</i> , 1999 , 11, 664-72	4	73
48	Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. <i>Nature</i> , 1998 , 396, 699-703	50.4	658
47	Identification of a ligand for the death-domain-containing receptor Apo3. <i>Current Biology</i> , 1998 , 8, 525-86.3	172	
46	Death receptors: signaling and modulation. <i>Science</i> , 1998 , 281, 1305-8	33.3	4373
45	APO2 ligand: a novel lethal weapon against malignant glioma?. <i>FEBS Letters</i> , 1998 , 427, 124-8	3.8	145
44	Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1. <i>Journal of Biological Chemistry</i> , 1997 , 272, 14029-32	5.4	247
43	Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. <i>Science</i> , 1997 , 277, 818-21	33.3	1483
42	A novel receptor for Apo2L/TRAIL contains a truncated death domain. <i>Current Biology</i> , 1997 , 7, 1003-6	6.3	569
41	Immunoadhesins as research tools and therapeutic agents. <i>Current Opinion in Immunology</i> , 1997 , 9, 195-200	65	
40	Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. <i>Journal of Biological Chemistry</i> , 1996 , 271, 12687-90	5.4	1384
39	Ligand-induced assembly and activation of the gamma interferon receptor in intact cells. <i>Molecular and Cellular Biology</i> , 1996 , 16, 3214-21	4.8	117
38	Immunoadhesins: principles and applications. <i>Trends in Biotechnology</i> , 1996 , 14, 52-60	15.1	89
37	Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B. <i>Current Biology</i> , 1996 , 6, 1669-76	6.3	231
36	Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. <i>Current Biology</i> , 1996 , 6, 750-2	6.3	184

35	The third intracellular loop of the 5-hydroxytryptamine _{2A} receptor determines effector coupling specificity. <i>Journal of Neurochemistry</i> , 1995 , 64, 1440-7	6	14
34	A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells. <i>Stem Cells and Development</i> , 1995 , 4, 439-46		6
33	Immunoadhesins: An Alternative to Human Monoclonal Antibodies. <i>Methods</i> , 1995 , 8, 104-115	4.6	11
32	Ligand-induced autoregulation of IFN-gamma receptor beta chain expression in T helper cell subsets. <i>Science</i> , 1995 , 270, 1215-8	33.3	177
31	Interferon gamma signals via a high-affinity multisubunit receptor complex that contains two types of polypeptide chain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 5401-5	11.5	83
30	Protection against endotoxic shock by bactericidal/permeability-increasing protein in rats. <i>Journal of Clinical Investigation</i> , 1995 , 95, 1947-52	15.9	21
29	Protection against rat endotoxic shock by p55 tumor necrosis factor (TNF) receptor immunoadhesin: comparison with anti-TNF monoclonal antibody. <i>Journal of Infectious Diseases</i> , 1994 , 170, 1323-6	7	34
28	Modification of CD4 immunoadhesin with monomethoxypoly(ethylene glycol) aldehyde via reductive alkylation. <i>Bioconjugate Chemistry</i> , 1994 , 5, 133-40	6.3	39
27	Liposome targeting to human immunodeficiency virus type 1-infected cells via recombinant soluble CD4 and CD4 immunoadhesin (CD4-IgG). <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1994 , 1194, 185-96	3.8	26
26	Generation of soluble interleukin-1 receptor from an immunoadhesin by specific cleavage. <i>Molecular Immunology</i> , 1994 , 31, 1335-44	4.3	15
25	Molecular and biological properties of an interleukin-1 receptor immunoadhesin. <i>Molecular Immunology</i> , 1994 , 31, 1345-51	4.3	11
24	Biochemical characterization of the extracellular domain of the 75-kilodalton tumor necrosis factor receptor. <i>Biochemistry</i> , 1993 , 32, 3131-8	3.2	46
23	Immunoadhesins. <i>International Reviews of Immunology</i> , 1993 , 10, 219-27	4.6	42
22	Cloning and expression of a human CDC42 GTPase-activating protein reveals a functional SH3-binding domain. <i>Journal of Biological Chemistry</i> , 1993 , 268, 26059-62	5.4	89
21	A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT _{1B} receptors. <i>Nature</i> , 1992 , 360, 161-3	50.4	273
20	Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. <i>Journal of Virology</i> , 1992 , 66, 235-43	6.6	248
19	Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991 , 88, 10535-9	11.5	228
18	Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-gp120 binding affinity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991 , 88, 7056-60	11.5	89

17	Mapping the CD4 binding site for human immunodeficiency virus by alanine-scanning mutagenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990 , 87, 7150-4	11.5	152
16	Enzymatic cleavage of a CD4 immunoadhesin generates crystallizable, biologically active Fd-like fragments. <i>Biochemistry</i> , 1990 , 29, 9885-91	3.2	34
15	The MHC-binding and gp120-binding functions of CD4 are separable. <i>Science</i> , 1989 , 245, 743-6	33.3	140
14	Acetylcholine analogue stimulates DNA synthesis in brain-derived cells via specific muscarinic receptor subtypes. <i>Nature</i> , 1989 , 340, 146-50	50.4	239
13	Functionally distinct G proteins selectively couple different receptors to PI hydrolysis in the same cell. <i>Cell</i> , 1989 , 56, 487-93	56.2	265
12	Solubilization and characterization of lactogenic hormone receptor from kidney of lactating cow. <i>Molecular and Cellular Endocrinology</i> , 1989 , 61, 77-85	4.4	6
11	Inhibition of the proliferation of Nb2 cells by femtomolar concentrations of cholera toxin and partial reversal of the effect by 12-O-tetradecanoyl-phorbol-13-acetate. <i>Journal of Cellular Biochemistry</i> , 1988 , 37, 119-29	4.7	15
10	Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes. <i>Nature</i> , 1988 , 334, 434-7	50.4	632
9	An M2 muscarinic receptor subtype coupled to both adenylyl cyclase and phosphoinositide turnover. <i>Science</i> , 1987 , 238, 672-5	33.3	367
8	A comparative study of lactogenic hormone binding sites in the adrenal gland, ovary and kidney of the lactating cow. <i>Journal of Receptors and Signal Transduction</i> , 1987 , 7, 921-36		4
7	Partial purification and characterization of bovine mammary gland prolactin receptor. <i>Molecular and Cellular Endocrinology</i> , 1987 , 50, 79-87	4.4	12
6	Characterization of lactogen receptors in lactogenic hormone-dependent and independent NB2 lymphoma cell lines. <i>FEBS Letters</i> , 1987 , 210, 51-5	3.8	18
5	Primary structure and biochemical properties of an M2 muscarinic receptor. <i>Science</i> , 1987 , 236, 600-5	33.3	497
4	Comparative study of in vitro and in vivo modulation of lactogenic and somatotrophic receptors by native human growth hormone and its modified analog prepared by recombinant deoxyribonucleic acid technology. <i>Endocrinology</i> , 1987 , 121, 414-9	4.8	22
3	Inhibition of lactogenic activities of ovine prolactin and human growth hormone (hGH) by a novel form of a modified recombinant hGH. <i>Endocrinology</i> , 1986 , 118, 720-6	4.8	41
2	Binding sites of human growth hormone and ovine and bovine prolactins in the mammary gland and the liver of lactating dairy cow. <i>Molecular and Cellular Endocrinology</i> , 1984 , 34, 51-7	4.4	76
1	Noncanonical mRNA decay by the endoplasmic-reticulum stress sensor IRE1 promotes cancer-cell survival		3